Organon (OGN) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Organon (OGN) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -92.23% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.33% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 65.85% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -635.24% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -108.13% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -69.68% |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | -25.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.52% |
| Mar 31, 2026 | 67.82% |
| Dec 31, 2025 | -288.07% |
| Sep 30, 2025 | -55.43% |
| Jun 30, 2025 | -25.64% |
| Mar 31, 2025 | -56.72% |
| Dec 31, 2024 | -80.04% |
| Sep 30, 2024 | 518.97% |
| Jun 30, 2024 | -19.42% |
| Mar 31, 2024 | 13.56% |
| Jun 30, 2021 | 90.91% |
| Mar 31, 2021 | 112.90% |